Biocon Secures Dual Health Canada NOC for Denosumab Biosimilars

Biocon has cleared a significant regulatory threshold in Canada, receiving a Notice of Compliance (NOC) from Health Canada on April 3, 2026, for two denosumab biosimilars: Bosaya (60 mg/mL prefilled syringe for subcutaneous use) and Vevzuo (120 mg/1.7 mL single-dose vial for subcutaneous use). The dual approval, covering both the Prolia and Xgeva reference product indications, signals that Biocon's comparability data package satisfied Health Canada's biosimilar guidance requirements across analytical, nonclinical, and clinical domains -- a package the company states demonstrated no clinically meaningful differences in quality, safety, or efficacy relative to the respective reference products.

For QA and regulatory teams tracking biosimilar approval trends in Canada, the scope of the approved indications is operationally relevant. Bosaya carries approvals spanning postmenopausal osteoporosis, male osteoporosis, bone loss associated with androgen deprivation therapy in nonmetastatic prostate cancer, bone loss associated with adjuvant aromatase inhibitor therapy in nonmetastatic breast cancer, and glucocorticoid-induced osteoporosis. Vevzuo is approved for reducing skeletal-related events in patients with multiple myeloma and bone metastases from breast, prostate, non-small cell lung cancer, and other solid tumours; giant cell tumour of bone that is unresectable or likely to result in severe morbidity with resection; and hypercalcemia of malignancy refractory to intravenous bisphosphonate. The breadth of indications across two distinct dosing presentations reflects the complexity of the comparability exercise required to support extrapolation across oncology and non-oncology settings.

Denosumab's mechanism -- a fully human monoclonal antibody targeting Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) -- places it among the more analytically demanding biosimilar programs. RANKL drives osteoclast formation, function, and survival; inhibiting it reduces bone resorption and increases bone mass and strength. Demonstrating biosimilarity for a monoclonal antibody of this class requires rigorous characterization of binding affinity, glycosylation profiles, and functional potency, all of which must be reflected in the manufacturing process and controlled under GMP-compliant systems. Health Canada's acceptance of Biocon's submission indicates the company's process validation and analytical comparability work met the evidentiary standard required under the Canadian biosimilar pathway.

From a patient access standpoint, Biocon estimates the approvals could benefit more than 2 million adults with osteoporosis in Canada, as well as patients annually managing bone metastasis as a complication of advanced cancer. Prescribers and formulary decision-makers will note that the approved labeling includes standard denosumab precautions: hypocalcemia must be corrected prior to initiating therapy, clinically significant hypersensitivity reactions including anaphylaxis have been reported, and serious infections leading to hospitalization have been observed in women with postmenopausal osteoporosis. The safety and efficacy of denosumab have not been studied in patients with hepatic impairment.

Shreehas Tambe, CEO and Managing Director of Biocon Ltd., stated that the approvals "reflect our strong scientific and regulatory capabilities" and reinforce the company's commitment to expanding access to affordable biologic therapies across immunology and oncology. Biocon is listed on both the BSE (532523) and NSE (BIOCON). The company has not disclosed a commercial launch date for either product in Canada.